Company Filing History:
1 out of 917 
1 out of 1,209 
Years Active: 2025
Title: Rachel Eclov: Innovator in Immunotherapy
Introduction
Rachel Eclov is a prominent inventor based in Chicago, IL, known for her significant contributions to the field of immunotherapy. With a focus on developing peptide-based therapeutics, she aims to enhance anti-tumor immune responses while minimizing the immuno-suppressive effects of regulatory T cells.
Latest Patents
Rachel holds a patent titled "Compositions and methods for inhibition of FOXP3." This innovative work provides peptide-based therapeutics that target FOXP3, which is crucial for decreasing the immuno-suppressive effects of Tregs. Her methods are designed to inhibit immune dysregulation, particularly in contexts such as anti-tumor immune responses, autoimmunity, and inflammatory conditions.
Career Highlights
Throughout her career, Rachel has worked with esteemed institutions, including the University of Chicago and Dana-Farber Cancer Institute. Her research has been pivotal in advancing the understanding of immune responses and developing new therapeutic strategies.
Collaborations
Rachel has collaborated with notable colleagues, including James LaBelle and Gregory H Bird, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Rachel Eclov's work in immunotherapy exemplifies the impact of innovative research on healthcare. Her dedication to developing effective treatments showcases the potential of targeted therapies in combating various diseases.